The therapeutic potential of TNFR2 agonists and antagonists has been progressively more studied in the context of CD4+Treg expansion or depletion in both autoimmunity, GvHD, and cancer (121, 122). The gene discussed is TNFRSF1B; the disease is Autoimmunity.